☆ 4.4 Article

Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection

MSPHERE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Immunology

The presence of serum anti-SARS-CoV-2 IgA appears to protect primary health care workers from COVID-19

Viktoria Hennings et al.

Summary: The patterns of humoral and cellular responses to SARS-CoV-2 were studied in Swedish primary health care workers, and it was found that contracting Covid-19 was associated with specific antibody and T cell responses, as well as certain clinical factors, while not contracting the infection was associated with other antibody responses, allergy, and smoking.

EUROPEAN JOURNAL OF IMMUNOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2

Leo Swadling et al.

Summary: Research suggests that some individuals can clear potential SARS-CoV-2 infection after exposure, with T cells playing a role in the process. Studying healthcare workers who tested negative for antibodies revealed that they had stronger and more diverse memory T cells, with a focus on RTC.

NATURE (2022)

添加到收藏夹

Article Medicine, General & Internal

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients

Lorenzo Azzi et al.

Summary: BNT162b2 COVID-19 vaccine induces strong systemic immune response but poorly activates mucosal immunity.

EBIOMEDICINE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Humoral and cellular immune memory to four COVID-19 vaccines

Zeli Zhang et al.

Summary: Multiple COVID-19 vaccines have successfully protected against symptomatic cases and deaths. Comparisons of T cell, B cell, and antibody responses to different vaccines can provide insights into protective immunity against COVID-19, particularly immune memory. mRNA vaccines and Ad26.COV2.S induced strong T cell responses, while mRNA vaccines showed substantial declines in antibodies.

CELL (2022)

添加到收藏夹

Article Medicine, Research & Experimental

BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?

Abbass Darwich et al.

Summary: Vaccination induces the development of mucosal antibodies, protecting against infection. IgG antibodies from plasma can be detected in saliva after receiving the BNT162b2 vaccine, but IgA1 levels are low.

EMBO MOLECULAR MEDICINE (2022)

添加到收藏夹

Article Immunology

Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection

Salma Sheikh-Mohamed et al.

Summary: Although SARS-CoV-2 mainly infects the upper respiratory tract, little is known about the antibodies generated in the oral cavity in response to COVID-19 vaccination. This study found that most participants had detectable antibodies in their saliva after the first dose of mRNA vaccine. The second dose boosted the IgG response but had little effect on the IgA response. Participants with lower levels of vaccine-induced IgA were more likely to experience breakthrough infections.

MUCOSAL IMMUNOLOGY (2022)

添加到收藏夹

Article Medical Laboratory Technology

Validation of COVID-19 serologic tests and large scale screening of asymptomatic healthcare workers

Kristin E. Mullins et al.

Summary: The study validated two serologic tests for SARS-CoV-2 antibodies in asymptomatic healthcare workers and found high sensitivity and specificity. Parallel orthogonal testing improves the accuracy of serologic testing in populations with low prevalence.

CLINICAL BIOCHEMISTRY (2021)

添加到收藏夹

Article Cell Biology

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Zijun Wang et al.

Summary: The IgA response to SARS-CoV-2 was characterized in a cohort of 149 convalescent individuals after COVID-19 diagnosis. IgA responses in plasma generally correlated with IgG responses, and B cells producing IgM, IgG, and IgA were derived from common progenitor cells. Notably, IgA dimers were found to be 15 times more potent than IgA monomers against SARS-CoV-2, suggesting their potential value for protection and vaccine efficacy.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Sara Y. Tartof et al.

Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.

LANCET (2021)

添加到收藏夹

Article Infectious Diseases

Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021

Kamal Abu Jabal et al.

Summary: An analysis of 514 Israeli healthcare workers showed that the BNT162b2 mRNA COVID-19 vaccine had similar immunogenicity by ethnicity and sex, but decreased with age. Individuals with prior COVID-19 infection had significantly higher antibody titres compared to those who were naive, regardless of pre-vaccination IgG levels.

EUROSURVEILLANCE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants

Emanuele Andreano et al.

Summary: Research suggests that individuals who have been infected or vaccinated for the first time will produce antibodies with increased potency and breadth, allowing for better control of emerging SARS-CoV-2 variants.

NATURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Shuo Feng et al.

Summary: Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine were identified as correlates of protection against symptomatic infection. Higher levels of immune markers were correlated with a reduced risk of symptomatic infection. The data can be used to extrapolate efficacy estimates to new populations.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK

Koen B. Pouwels et al.

Summary: A large, community-based study in the United Kingdom indicates that the effectiveness of BNT162b2 and ChAdOx1 vaccines against SARS-CoV-2 infections with symptoms or high viral burden is reduced with the Delta variant compared to the Alpha variant. Although the effectiveness of two doses is at least as great as protection afforded by prior natural infection, there are significant differences in the dynamics of immunity after the second dose between BNT162b2 and ChAdOx1.

NATURE MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

Saman Saadat et al.

Summary: This study compared the titers of binding and neutralizing antibodies in healthcare workers previously infected with SARS-CoV-2 after receiving a single dose of mRNA coronavirus vaccine.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Waning Immunity after the BNT162b2 Vaccine in Israel

Yair Goldberg et al.

Summary: The immunity against the delta variant of SARS-CoV-2 waned in all age groups in Israel a few months after receiving the second dose of the vaccine, leading to an increase in infection and severe cases.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Einav G. Levin et al.

Summary: A study in Israel revealed that waning immunity after receiving two doses of the BNT162b2 vaccine led to an increase in the incidence of SARS-CoV-2 infection. Levels of spike-binding IgG and neutralizing antibodies decreased more significantly in men, individuals aged 65 or older, and immunosuppressed individuals in a longitudinal study involving nearly 4000 healthcare workers.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Microbiology

Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays

Georg Semmler et al.

Summary: This study found that differences in sensitivity among commercial immunoassays during acute SARS-CoV-2 infection are only partly related to the target antigen. NCP-specific IgA and IgG antibodies are detected earlier, while higher levels of S1-specific IgA antibodies occur in severely ill patients.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Charlotte Manisty et al.

LANCET (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Florian Krammer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination

Aubree Mades et al.

Summary: COVID-19 mRNA vaccines are highly effective in preventing COVID-19. All participants developed detectable oral mucosal SARS-CoV-2 IgG antibodies within 15 days after receiving the first vaccine dose. There were no significant differences in oral mucosal antibody concentrations once participants were fully vaccinated with Moderna and Pfizer/BioNTech vaccines.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Joseph E. Ebinger et al.

Summary: Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals. Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.

NATURE MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Leonidas Stamatatos et al.

Summary: The study found that vaccination of both previously infected individuals and those who were not infected resulted in increased neutralizing antibody titers, with previously infected individuals showing a greater boost in neutralizing titers. Vaccination of naive individuals also elicited cross-neutralizing responses, but at lower titers.

SCIENCE (2021)

添加到收藏夹

Article Immunology

Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals after mRNA vaccination

Rishi R. Goel et al.

Summary: mRNA vaccines exhibit robust serological and cellular priming, with naïve individuals requiring two doses for optimal antibody responses, especially against the B.1.351 variant. Memory B cells specific for spike protein and RBD were efficiently primed by vaccination, while recovered individuals showed significant boosting after the first dose, correlating with preexisting memory B cell levels. Identifying distinct responses based on prior SARS-CoV-2 exposure suggests that recovered subjects may only need one vaccine dose for peak responses, which can inform vaccine distribution strategies in resource-limited settings.

SCIENCE IMMUNOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals

Elizabeth Fraley et al.

Summary: This study characterized humoral immune responses during vaccination with the BNT162b2 vaccine in individuals with or without prior history of natural SARS-CoV-2 infection, demonstrating differences in antibody levels and epitope specificity between the two groups. The findings support the consideration of prior infection history as a guide for future vaccination strategies and provide valuable insights for vaccine development.

BMC MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Zijun Wang et al.

Summary: Despite challenges posed by COVID-19 variants, convalescent individuals receiving mRNA vaccines exhibit robust and long-lasting immune responses against circulating SARS-CoV-2 variants, providing hope for effective control of the pandemic.

NATURE (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

S. J. Thomas et al.

Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination

Lucie Loyal et al.

Summary: The study demonstrates that preexisting spike-cross-reactive T cells play a functional role in the immune response to SARS-CoV-2 infection and vaccination. Cross-reactive immunity may explain the rapid induction of immunity after primary SARS-CoV-2 immunization and the high rate of asymptomatic or mild COVID-19 cases.

SCIENCE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells

Jose Mateus et al.

Summary: This study examined the immune responses to the Moderna mRNA-1273 vaccine over 7 months, finding that subjects with preexisting cross-reactive T cell memory exhibited stronger CD4(+) T cell and antibody responses to the vaccine. This demonstrates the biological relevance and potential importance of cross-reactive T cells in generating immunity to SARS-CoV-2.

SCIENCE (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021

Srinivas Nanduri et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021

Alyson M. Cavanaugh et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

添加到收藏夹

Article Cell Biology

Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity

Jennifer L. Yates et al.

Summary: The severity of COVID-19 is associated with elevated levels of SARS-CoV-2-specific antibodies in severe cases, with spike-specific IgG subclass utilization potentially contributing to disease severity through potent Fc-mediated effector functions. These findings may have significant implications for SARS-CoV-2 vaccine design and convalescent plasma therapy.

CELL REPORTS MEDICINE (2021)

添加到收藏夹

Article Medicine, Research & Experimental

One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19

Riccardo Levi et al.

Summary: A study showed that individuals with prior exposure to SARS-CoV-2 had a significant increase in antibody response within 5 to 18 days after receiving the Pfizer/BioNTech vaccine. Symptomatic individuals reached a high titer of antibodies with just one dose, suggesting that a second dose may not be necessary.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Alba Grifoni et al.

CELL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Jose Mateus et al.

SCIENCE (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population

Sabra Klein et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

添加到收藏夹

Article Immunology

SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors

Sarah E. Benner et al.

JOURNAL OF INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Medicine, General & Internal

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Virology

Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients

Anwar M. Hashem et al.

VIRUSES-BASEL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays

Zahra Rikhtegaran Tehrani et al.

PLOS ONE (2020)

添加到收藏夹

Article Immunology

Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers

Matthias G. Pauthner et al.

IMMUNITY (2019)

添加到收藏夹

Article Immunology

A Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood

Jennifer M. Dan et al.

JOURNAL OF IMMUNOLOGY (2016)

添加到收藏夹

Article Immunology

Cytokine-Independent Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman Primates Using a Live Cell Activation-Induced Marker Technique

Colin Havenar-Daughton et al.

JOURNAL OF IMMUNOLOGY (2016)

添加到收藏夹

Review Immunology

Regulation of the polymeric immunoglobulin receptor and IgA transport: new advances in environmental factors that stimulate pIgR expression and its role in mucosal immunity

F-E Johansen et al.

MUCOSAL IMMUNOLOGY (2011)

添加到收藏夹

Article Immunology

Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: Functional expression of FcRn in the mammalian lung

GM Spiekermann et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.